AI Account-Based Marketing for Medical Devices & MedTech

The Account-Based Marketing challenge for Medical Devices & MedTech

Medical device marketing that drives adoption requires simultaneous execution on three tracks: clinical evidence (peer-reviewed publications, society presentation abstracts, clinical registry participation), economic justification (published health economic analyses, cost-per-procedure comparisons, length-of-stay impact), and reimbursement support (CPT code coverage, coverage determination letters, payer medical policies). Skipping any track creates a sales ceiling that no campaign can overcome. Sunshine Act-compliant KOL relationship management — where physician education funding and speaking fees are properly documented and reported — is both a compliance requirement and a marketing asset: disclosed, transparent relationships with recognized clinical experts build more credibility than undisclosed ones.

On Account-Based Marketing specifically, Medical Devices & MedTech teams run into: Hospital value analysis committee (VAC) reviews are the primary purchase gate for capital equipment and novel devices — a device that has clinical champion support but fails economic justification (no published cost-effectiveness data, no reimbursement code, no comparable reduction in length of stay) does not get approved; GPO (Group Purchasing Organization) contract coverage is prerequisite for reaching most US hospital systems at scale — marketing to hospitals not on your GPO contract generates clinical interest that procurement can't fulfill, wasting sales resources on unconvertible prospects; FDA clearance and approval claims require extraordinary precision — marketing materials must use only cleared indications, cannot imply off-label use, and must include required device labeling language even in digital ad formats where character limits are real; Clinical evidence generation is a long-cycle investment (3–7 years for RCT evidence) that competes with short-cycle commercial pressure — medtech companies that don't invest in evidence early face a permanent credibility ceiling against competitors who did; Physician preference and KOL endorsement drive adoption in surgical and interventional specialties, but KOL relationships are subject to Sunshine Act reporting requirements that create compliance exposure if not managed correctly. FDA 21 CFR Part 807 (510(k) clearance process); FDA 21 CFR Part 814 (PMA process for Class III devices); FDA Off-Label Promotion prohibition (device labeling and promotion must match cleared indications); Physician Payments Sunshine Act (Open Payments) reporting for physician KOL relationships; Anti-Kickback Statute implications for device incentives; HIPAA for any patient data used in clinical studies; EU MDR (Medical Device Regulation) and IVDR for European device marketing; ISO 13485 quality system certification as marketing credibility signal; GDPR for clinical study and registry data involving EU patients

How Hadrian's ABM Agent runs Account-Based Marketing for Medical Devices & MedTech

AI monitors engagement signals across hundreds of target accounts simultaneously and drafts personalized assets per account — humanly impossible to do at this scale without a large ABM team. The agent reads CRM account records (industry, ARR, headcount, deal stage, last activity), Intent data (Bombora, 6sense — topic surge by account domain), LinkedIn Ads Campaign Manager (account-matched audience performance), Website analytics (Clearbit Reveal / RB2B — de-anonymized account visits) and runs: Build and maintain a tiered target account list (Tier 1/2/3) using ICP scoring against CRM and third-party data; Monitor target account engagement signals: ad impressions, website visits, content downloads, intent spikes; Generate personalized landing pages, one-pagers, and email sequences for Tier-1 accounts; Coordinate account plays with AEs: surface warm signals, suggest next-best action, draft outreach; Run account-level ad campaigns on LinkedIn with matched audiences refreshed weekly; Produce quarterly account coverage and pipeline velocity report by tier — applied to Medical Devices & MedTech context.

For Medical Devices & MedTech that means coordinated execution across Clinical specialty society conferences (ACC, ASN, AAOS, AANS, SAGES, DDW — by clinical specialty), Medical device trade publications (MedCity News, MassDevice, Fierce Medtech, Medical Design & Outsourcing), LinkedIn (CMO or Chief Medical Officer at health systems, OR/cath lab directors, surgeon KOLs, Hospital Value Analysis Coordinator), GPO marketing programs (Vizient, Premier, HealthTrust preferred vendor marketing channels), Clinical society exhibit halls and physician education programs (CME-supported symposia around major meetings) without adding headcount, with a human approval gate before anything publishes or spends.

What you get

Outputs: Tiered target account list (refreshed monthly, scored, with rationale), Account engagement heatmap (by tier and stage — weekly), Personalized account assets (landing pages, one-pagers, email sequences), ABM pipeline report (account-attributed pipeline by tier, quarterly) — tuned to Medical Devices & MedTech buyers (VP Marketing or VP Commercial at a medical device manufacturer (Series C through public); Product Manager responsible for a specific device line; VP Sales or National Accounts Director managing GPO relationships and IDN accounts; at health systems, a Value Analysis Coordinator or Director of Supply Chain evaluating device portfolios; Interventional Cardiologist, Orthopedic Surgeon, or specialty physician as clinical evaluator and champion) and moving Target account pipeline coverage (% of Tier-1 accounts with open opportunity), Account engagement rate (% of target accounts with 2+ marketing touches/month), ABM-attributed pipeline velocity (days from first touch to SQL for target accounts). The ABM Agent works alongside Hadrian's other agents so Account-Based Marketing stays aligned with the rest of your marketing.

RELATED